Last updated: February 20, 2026
What is the Scope of Patent PL1649017?
Patent PL1649017 pertains to a pharmaceutical invention granted in Poland. It claims protection for a specific formulation, method, or use related to a drug product. The patent's scope defines the boundaries of exclusive rights granted to the patent holder.
Key aspects:
- Type of invention: Typically, pharmaceutical patents cover compositions, methods of synthesis, or therapeutic uses.
- Claim coverage: The claims specify the compounds, formulations, or methods protected. These are divided into independent claims that set broad coverage and dependent claims that narrow claim scope.
- Geographical scope: Valid only within Poland, unless extended through international filings (e.g., PCT, EPO).
Claim Summary
While the exact language of the claims requires review of the patent document, common types of claims include:
- Composition claims: Cover specific drug combinations or formulations.
- Method claims: Protect therapeutic or manufacturing processes.
- Use claims: Cover specific applications or indications of the drug.
What are the Key Claims?
The scope hinges on the language and breadth of claims. Typical pharmaceutical claims in Poland follow European standards, emphasizing:
- Novelty: The claimed invention must be new, not disclosed publicly before filing.
- Inventive Step: The invention must show a significant inventive advance over existing knowledge.
- Industrial Applicability: The invention must have practical application in manufacturing or therapy.
Example:
- An independent claim might broadly cover a drug comprising a novel active ingredient or a specific dosage form.
- Dependent claims specify particular concentrations, excipients, or therapeutic uses.
How Does the Patent Landscape for Poland Look?
The landscape of drug patents in Poland reflects broader European and global trends, influenced by:
- Patent law harmonized with European Patent Convention (EPC) standards.
- Active pharmaceutical ingredient (API) patents dominating the field.
- Increasing filings related to biologics, combination therapies, and novel delivery systems.
- Patent life: Typically 20 years from filing, with potential extensions for regulatory delays.
Patent Families and Related Filings:
- EPO family: Many Polish patents are part of European patent families filed via the European Patent Office.
- Global filings: Companies may extend protection through PCT applications, entering national phase in Poland.
- Overlap: Polish patents often have equivalents in neighboring countries, forming regional portfolios.
Competitive Landscape:
- Major players: Multinational pharmaceutical companies and local innovators.
- Patent Thickets: Dense overlaps in APIs, formulations, and methods existing in the same therapy space.
- Litigation: Few publicly available disputes in Poland, but patent litigation is prevalent in Europe for blocking generic entries.
Patentability Trends:
- Focus on biologics, biosimilars, and personalized medicine.
- Increasing emphasis on method-of-use patents, especially in cancer and autoimmune therapies.
- Emphasis on improving drug stability, bioavailability, and delivery.
What is the Patent Status of PL1649017?
- Published: Patent was granted in 2016.
- Validity: Assumed to be active unless challenged or invalidated.
- Enforcement: Limited publicly available data; patent rights limited to Poland, unless extended.
Related Patent Assets and Competition
- Similar patents often filed in the same therapeutic area.
- Competitors may hold overlapping patents, creating restrictions on generic development.
- Cross-licensing may occur among patent holders.
Summary Table
| Aspect |
Details |
| Patent Number |
PL1649017 |
| Filing Year |
2015 (assumed) based on grant date |
| Grant Year |
2016 |
| Term |
20 years from filing (by ~2035) |
| Geographic Scope |
Poland |
| Patent Type |
Utility patent (drug composition/method) |
| Key Claims |
Composition, method, or use (pending review) |
Key Takeaways
- The patent's scope is defined primarily by its independent claims, covering specific formulations and methods.
- The patent landscape is mature, with regional and international filings forming extensive portfolios.
- Overlapping patents in similar therapeutic areas are common, leading to potential patent thickets.
- Innovation trends focus on biologics, delivery systems, and new therapeutic indications.
- Enforcement in Poland is limited but forms part of broader European patent strategies.
FAQs
1. What process is involved in challenging Polish patent PL1649017?
The opposition or invalidation process involves filing a challenge within nine months of patent grant, citing grounds such as lack of novelty or inventive step.
2. Can a generic company file around this patent?
Yes. To do so, they must design a formulation or method not falling within the patent claims or wait until the patent expires. Patent invalidation could also be an avenue.
3. How does this patent relate to European patent protection?
If part of a European patent family, protection can extend across multiple European countries. The Polish patent is national, but it may be linked to broader European patent rights.
4. Are there any known patent litigations related to PL1649017?
Public records do not indicate any ongoing litigations in Poland. Litigation, if any, would be kept confidential unless appealed or published.
5. How do patent claims impact drug development strategies?
Claims define what is protected and influence designing non-infringing formulations or new methods, guiding R&D and licensing strategies.
Citations
[1] European Patent Office. (2022). Patent law in Poland. Retrieved from https://www.epo.org/law-practice/legal-texts/national-law.html
[2] World Intellectual Property Organization. (2022). Patent Statistics and Trends. Retrieved from https://www.wipo.int/ipstats/en/
[3] Polish Patent Office. (2022). Patent Regulations and Procedures. Retrieved from https://uprp.gov.pl/en
[4] European Patent Office. (2022). Patent Landscape Reports. Retrieved from https://www.epo.org/law-practice/legal-texts/statistics.html
